
SGLT2 Inhibitors Linked to Improved Outcomes in ATTR Amyloidosis With Cardiomyopathy
Although sodium-glucose cotransporter 2 (SGLT2) inhibitors have become a mainstay in managing heart failure with preserved and reduced ejection fraction, patients with cardiac transthyretin (ATTR) amyloidosis are often excluded from clinical trials …